What's in National Jewish Health's pipeline?

National Jewish Health has 9 drugs in our index: 5 marketed, 0 filed, 0 in Phase 3, 2 in Phase 2, 2 in Phase 1.

Which companies overlap with National Jewish Health's portfolio?

Top competitors by shared drug class: Research in Real-Life Ltd, University Medical Center Groningen, GlaxoSmithKline, Istituto per la Ricerca e l'Innovazione Biomedica, SkyePharma AG.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/national-jewish-health.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

National Jewish Health — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

National Jewish Health pipeline: 5 marketed, 0 filed, 0 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

5 marketed 0 filed 0 Phase 3 2 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
budesonide and formoterol	budesonide and formoterol	marketed	Corticosteroid [EPC]	Glucocorticoid receptor, beta 2 -adrenoceptor
Triple combination therapy	Triple combination therapy	marketed
Ipratropium/albuterol	Ipratropium/albuterol	marketed	Combination bronchodilator (anticholinergic + beta-2 agonist)	Muscarinic acetylcholine receptors (ipratropium); beta-2 adrenergic receptor (albuterol)	Respiratory/Pulmonology
Beclomethasone dipropionate HFA	Beclomethasone dipropionate HFA	marketed	Inhaled corticosteroid	Glucocorticoid receptor	Respiratory/Pulmonology
fluticasone propionate and salmeterol	fluticasone propionate and salmeterol	marketed	Inhaled corticosteroid/long-acting beta-2 agonist combination	Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (salmeterol)	Respiratory/Pulmonology

Therapeutic area mix

Other · 3
Respiratory/Pulmonology · 3
Infectious Disease · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Research in Real-Life Ltd · 2 shared drug classes
University Medical Center Groningen · 2 shared drug classes
GlaxoSmithKline · 2 shared drug classes
Istituto per la Ricerca e l'Innovazione Biomedica · 2 shared drug classes
SkyePharma AG · 2 shared drug classes
AstraZeneca · 2 shared drug classes
Chiesi Farmaceutici S.p.A. · 2 shared drug classes
University of Chicago · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for National Jewish Health:

Cite this brief

Drug Landscape (2026). National Jewish Health — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/national-jewish-health. Accessed 2026-05-17.